de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K
The median time to onset was 2.5 months (range 0 days3 years)
The design integrates several key components, as outlined below: the chosen CBBBP is Tat, identified through prior animal experimentation from two candidate peptides for its superior efficacy in facilitating the transport of therapeutic agents crossing BBB
I have blogged extensively about the metabolic crises in the US
Notably, liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial) have demonstrated cardiovascular benefits, including reductions in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
There is no point reducing side effects if you also eliminate the therapeutic benefit